As a result of their deliberations committees may make recommendations which they include in their reports for the consideration of the House of Commons or the Government. Recommendations related to this study are listed below.

Recommendation 1

That the Government of Canada implement a clear communications protocol between the Minister of Health and the Chairperson and members of the Patented Medicine Prices Review Board.

Recommendation 2

That the Government of Canada review the process by which it enacts Patented Medicine Prices Review Board regulatory reform.

Recommendation 3

That the Government of Canada review the way in which it interacts with the pharmaceutical industry as a regulated sector with monopolistic patent pricing power.

Recommendation 4

That the mandate of the Patented Medicine Prices Review Board be clarified. The Board should be mandated to ensure that the prices of patented medicines are not excessive while also ensuring that pricing does not ultimately limit patient access, particularly in the case of rare diseases.

Recommendation 5

That the Patented Medicine Prices Review Board review its internal operating rules to ensure that they are clear and transparent. In addition, members appointed to the organization should be provided with independent, external support to help them in the event of misunderstandings and issues.

Recommendation 6

That the Patented Medicine Prices Review Board consider case studies to gain insight into how its future Guidelines would be applied in practice and to have a firmer idea of their potential consequences on patients and the life sciences ecosystem.

Recommendation 7

That the Patented Medicine Prices Review Board include a broader range of stakeholders in policy development.

Recommendation 8

That the members of the Patented Medicine Prices Review Board always have real‑time access to the contents of submissions presented in consultations.

Recommendation 9

That a registry be created to track drug penetration rates in Canada and compare them with similar countries.

Recommendation 10

That the Government of Canada maintain a public registry of publicly funded innovations, alone or in partnership with the industry, and ensure that what it funds is available in the Canadian marketplace.